Image
quality-of-life

Quality of life

Overall condition was assessed at baseline and last visit on the seven-category Patient or Caregiver Global Impression of Change (GIC) scale. The patient’s overall condition improved by at least one category on the seven-category GIC scale. Improvements were based on measures of GIC scores at the last visit.

Lennox-Gastaut syndrome (LGS)

 

LGS patients and caregivers reported improvements on the GIC scale with Epidyolex and clobazam (CLB) vs. placebo.1

80%
vs. placebo
p<0.0001 & p=0.0003
Epidyolex 20 mg/kg/day
76%
vs. placebo
p=0.0005
Epidyolex 10 mg/kg/day
31–46%
Placebo

 

Dravet syndrome (DS)

 

DS caregivers reported improvements on the GIC scale with Epidyolex and clobazam vs. placebo.1

62–77%
vs. placebo
p=0.0018 and 0.0136
73%
vs. placebo
p=0.0009
Epidyolex 10 mg/kg/day
30–41%
Placebo

The post-hoc analysis has been prepared at the request of the CHMP, p-values for this analysis were found to be nominal.

Discover impact on patient lives

LGS and DS patients and caregivers reported improvements on the GIC scale with Epidyolex and clobazam vs. placebo.1

 

 


References

 

1. Epidyolex Summary of Product Characteristics (Date accessed: April 2021).